The safety committee of the European Medicines Agency (EMA) has recommended that the EU marketing licence for amfepramone obesity medicines be withdrawn.

The recommendation follows a review which found that safety measures around the use of these medicines have not been sufficiently effective. The medicines were being used for longer...